Inhibition of α-helix-mediated protein-protein interactions using designed molecules

Nature Chemistry

Volumn 5, Issue 3, 2013, Pages 161-173

  Azzarito, Valeria ^a   Long, Kérya ^a   Murphy, Natasha S ^a   Wilson, Andrew J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PROTEIN;

ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PROTEIN STRUCTURE, SECONDARY; PROTEINS; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84875436143     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1568     Document Type: Review

References (138)

1. Stumpf, M. P. H. et al. Estimating the size of the human interactome. Proc. Natl Acad. Sci. USA 105, 6959-6964 (2008).
2. Berg, T. Modulation of protein-protein interactions with small organic molecules. Angew. Chem. Int. Ed. 42, 2462-2481 (2003).
3. Wells, J. A. & McLendon, C. L. Reaching for high-hanging fruit in drug discovery. Nature 450, 1001-1009 (2007).
4. Surade, S. & Blundell, T. L. Structural biology and drug discovery of difcult targets: the limits of ligandability. Chem. Biol. 19, 42-50 (2012).
5. Yin, H. & Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. 44, 4130-4163 (2005).
6. Wilson, A. J. Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 38, 3289-3300 (2009).
7. Bullock, B. N., Jochim, A. L. & Arora, P. S. Assessing helical protein interfaces for inhibitor design. J. Am. Chem. Soc. 133, 14220-14223 (2011).
8. Edwards, T. & Wilson, A. Helix-mediated protein-protein interactions as targets for intervention using foldamers. Amino Acids 41, 743-754 (2011).
9. Henchey, L. K., Jochim, A. L. & Arora, P. S. Contemporary strategies for the stabilization of peptides in the α-helical conformation. Curr. Opin. Chem. Biol. 12, 692-697 (2008).
10. Davis, J. M., Tsou, L. K. & Hamilton, A. D. Synthetic non-peptide mimetics of alpha-helices. Chem. Soc. Rev. 36, 326-334 (2007).
11. Cummings, C. G. & Hamilton, A. D. Disrupting protein-protein interactions with non-peptidic, small molecule α-helix mimetics. Curr. Opin. Chem. Biol. 14, 341-346 (2010).
12. Stites, W. E. Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem. Rev. 97, 1233-1250 (1997).
13. Keskin, O., Gursoy, A., Ma, B. & Nussinov, R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact. Chem. Rev. 108, 1225-1244 (2008).
14. Babine, R. E. & Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 97, 1359-1472 (1997).
15. Clackson, T. & Wells, J. A. A hot-spot of binding-energy in a hormone-receptor interface. Science 267, 383-386 (1995).
16. Eyrisch, S. & Helms, V. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem. 50, 3457-3464 (2007).
17. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
18. L/Bim fragment complex: implications for Bim function. Immunity 19, 341-352 (2003).
19. Czabotar, P. E. et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl Acad. Sci. USA 104, 6217-6222 (2007).
20. Chen, L. et al. Diferential targetting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
21. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
22. Bruning, J. B. et al. Coupling of receptor conformation and ligand orientation determine graded activity. Nature Chem. Biol. 6, 837-843 (2010).
23. Los, M., Roodhart, J. M. L. & Voest, E. E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist 12, 443-450 (2007).
24. Hudis, C. A. Trastuzumab-mechansim of action and use in clinical practice. New Engl. J. Med. 357, 39-51 (2007).
25. Biologic drugs set to top 2012 sales. Nature Med. 18, 636 (2012).
26. Chin, J. W. & Schepartz, A. Design and evolution of a miniature Bcl-2 binding protein. Angew. Chem. Int. Ed. 40, 3806-3809 (2001).
27. Rutledge, S. E., Volkman, H. M. & Schepartz, A. Molecular recognition of protein surfaces: high afnity ligands for the CBPKIX domain. J. Am. Chem. Soc. 125, 14336-14347 (2003).
28. Gemperli, A. C., Rutledge, S. E., Maranda, A. & Schepartz, A. Paralog-selective ligands for Bcl-2 proteins. J. Am. Chem. Soc. 127, 1596-1597 (2005).
29. Volkman, H. M., Rutledge, S. E. & Schepartz, A. Binding mode and transcriptional activation potential of high afnity ligands for the CBP KIX domain. J. Am. Chem. Soc. 127, 4649-4658 (2005).
30. Vaz, B. et al. Computational design, synthesis, and evaluation of miniproteins as androgen receptor coactivator mimics. Chem. Commun. 5377-5379 (2009).
31. Phan, T., Nguyen, H. D., Goksel, H., Mocklinghof, S. & Brunsveld, L. Phage display selection of miniprotein binders of the estrogen receptor. Chem. Commun. 46, 8207-8209 (2010).
32. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
33. Grasberger, B. L. et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48, 909-912 (2005).
34. Shangary, S. et al. Temporal activation of p53 by a specifc MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA 105, 3933-3938 (2008).
35. Rew, Y. et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem. 55, 4936-4954 (2012).
36. Hajduk, P. J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature Rev. Drug Discov. 6, 211-219 (2007).
37. Bruncko, M. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641-662 (2007).
38. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
39. Zhou, H. et al. Design of Bcl-2 and Bcl-xl inhibitors with subnanomolar binding afnities based upon a new scafold. J. Med. Chem. 55, 4664-4682 (2012).
40. Zhou, H. et al. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. J. Med. Chem. 55, 6149-6161 (2012).
41. Marshall, S. A., Lazar, G. A., Chirino, A. J. & Desjarlais, J. R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212-221 (2003).
42. Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classifcation. Nature Rev. Drug Discov. 7, 21-39 (2008).
43. Scholtz, J. M. & Baldwin, R. L. The mechanism of alpha-helix formation by peptides. Annu. Rev. Biophys. Biomol. Struct. 21, 95-118 (1992).
44. Andrews, M. J. I. & Tabor, A. B. Forming stable helical peptides using natural and artifcial amino acids. Tetrahedron 55, 11711-11743 (1999).
45. Garner, J. & Harding, M. M. Design and synthesis of α-helical peptides and mimetics. Org. Biomol. Chem. 5, 3577-3585 (2007).
46. Seebach, D. et al. Biological and pharmacokinetic studies with β-peptides. Chimia 52, 734-739 (1998).
47. Glickson, J. D. & Applequi, J. Conformation of poly-beta-alanine in aqueous solution from proton magnetic resonance and deuterium exchange studies. J. Am. Chem. Soc. 93, 3276-3281 (1971).
48. Gellman, S. H. Foldamers: A manifesto. Acc. Chem. Res. 31, 173-180 (1998).
49. Cheng, R. P., Gellman, S. H. & DeGrado, W. F. β-Peptides: from structure to function. Chem. Rev. 101, 3219-3232 (2001).
50. Pellegrini, M., Royo, M., Chorev, M. & Mierke, D. F. Conformational consequences of i, i+3 cystine linkages: Nucleation for α-helicity? J. Pept. Res. 49, 404-414 (1997).
51. Galande, A. K. et al. Potent inhibitors of LXXLL-based protein-protein interactions. ChemBioChem 6, 1991-1998 (2005).
52. Leduc, A. M. et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl Acad. Sci. USA 100, 11273-11278 (2003).
53. Galande, A. K., Bramlett, K. S., Burris, T. P., Wittlif, J. L. & Spatola, A. F. Tioether side chain cyclization for helical peptide formation: Inhibitors of estrogen receptor-coactivator interactions. J. Pept. Res. 63, 297-302 (2004).
54. Chorev, M. et al. Cyclic parathyroid-hormone related protein antagonists-lysine-13 to aspartic-acid 17 i to (i + 4) side-chain to side-chain lactamization. Biochemistry 30, 5968-5974 (1991).
55. Geistlinger, T. R. & Guy, R. K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc. 125, 6852-6853 (2003).
56. Judice, J. K. et al. Inhibition of HIV Type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc. Natl Acad. Sci. USA 94, 13426-13430 (1997).
57. Sia, S. K., Carr, P. A., Cochran, A. G., Malashkevich, V. N. & Kim, P. S. Short constrained peptides that Inhibit HIV-1 entry. Proc. Natl Acad. Sci. USA 99, 14664-14669 (2002).
58. Harrison, R. S. et al. Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc. Natl Acad. Sci. USA 107, 11686-11691 (2010).
59. Blackwell, H. E. & Grubbs, R. H. Highly efcient synthesis of covalently cross-linked peptide helices by ring-closing metathesis. Angew. Chem. Int. Ed. 37, 3281-3284 (1998).
60. Schafmeister, C. E., Po, J. & Verdine, G. L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891-5892 (2000).
61. Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
62. Walensky, L. D. et al. A stapled BID BH3 helix directly binds and activates Bax. Mol. Cell 24, 199-210 (2006).
63. Braun, C. R. et al. Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem. Biol. 17, 1325-1333 (2010).
64. Stewart, M. L., Fire, E., Keating, A. E. & Walensky, L. D. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nature Chem. Biol. 6, 595-601 (2010).
65. Bernal, F. et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18, 411-422 (2010).
66. Baek, S. et al. Structure of the stapled p53 peptide bound to Mdm2. J. Am. Chem. Soc. 134, 103-106 (2011).
67. Phillips, C. et al. Design and structure of stapled peptides binding to estrogen receptors. J. Am. Chem. Soc. 133, 9696-9699 (2011).
68. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
69. Bird, G. H. et al. Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc. Natl Acad. Sci. USA 107, 14093-14098 (2010).
70. Cabezas, E. & Satterthwait, A. C. The hydrogen-bond mimic approach: solid phase synthesis of a peptide stabilized as an α-helix with a hydrazone link. J. Am. Chem. Soc. 121, 3862-3875 (1999).
71. Patgiri, A., Jochim, A. L. & Arora, P. S. A Hydrogen-bond surrogate approach for stabilization of short peptide sequences in α-helical conformation. Acc. Chem. Res. 41, 1289-1300 (2008).
72. Chapman, R. N., Dimartino, G. & Arora, P. S. A highly stable short α-helix constrained by a main-chain hydrogen-bond surrogate. J. Am. Chem. Soc. 126, 12252-12253 (2004).
73. Wang, D. Y., Liao, W. & Arora, P. S. Binding properties of artifcial α-helices derived from a hydrogen-bond surrogate: application to Bcl-xL. Angew. Chem. Int. Ed. 44, 6525-6529 (2005).
74. Wang, D., Lu, M. & Arora, P. S. Inhibition of HIV-1 fusion by hydrogen-bond-surrogate-based α-helices. Angew. Chem. Int. Ed. 47, 1879-1882 (2008).
75. Henchey, L. K., Porter, J. R., Ghosh, I. & Arora, P. S. High specifcity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex. ChemBioChem 11, 2104-2107 (2010).
76. Henchey, L. K. et al. Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate α-helix. J. Am. Chem. Soc. 132, 941-943 (2010).
77. Patgiri, A., Yadav, K. K., Arora, P. S. & Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. Nature Chem. Biol. 7, 585-587 (2011).
78. Mahon, A. B. & Arora, P. S. Design, synthesis and protein-targeting properties of thioether-linked hydrogen bond surrogate helices. Chem. Commun. 1416-1418 (2011).
79. Muppidi, A. et al. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J. Am. Chem. Soc. 134, 14734-14737 (2012).
80. Jo, H. et al. Development of α-helical calpain probes by mimicking a natural protein-protein interaction. J. Am. Chem. Soc. 134, 17704-17713 (2012).
81. L. ChemBioChem 9, 3046-3054 (2008).
82. L. J. Am. Chem. Soc. 134, 7644-7647 (2012).
83. English, E. P., Chumanov, R. S., Gellman, S. H. & Compton, T. Rational development of β-peptide inhibitors of human cytomegalovirus entry. J. Biol. Chem. 281, 2661-2667 (2006).
84. Kritzer, J. A., Lear, J. D., Hodsdon, M. E. & Schepartz, A. Helical β-peptide inhibitors of the p53-hDM2 interaction. J. Am. Chem. Soc. 126, 9468-9469 (2004).
85. Harker, E. A., Daniels, D. S., Guarracino, D. A. & Schepartz, A. β-Peptides with improved afnity for hDM2 and hDMX. Bioorg. Med. Chem. 17, 2038-2046 (2009).
86. Hintersteiner, M. et al. A highly potent and cellularly active β-peptidic inhibitor of the p53/hDM2 interaction. ChemBioChem 10, 994-998 (2009).
87. Stephens, O. M. et al. Inhibiting HIV fusion with a β-peptide foldamer. J. Am. Chem. Soc. 127, 13126-13127 (2005).
88. Acton, S. et al. Identifcation of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518-520 (1996).
89. Werder, M., Hauser, H., Abele, S. & Seebach, D. β-Peptides as inhibitors of small-intestinal cholesterol and fat absorption. Helv. Chim. Acta 82, 1774-1783 (1999).
90. L recognition: Toward general strategies for foldamer-based inhibition of protein-protein interactions. J. Am. Chem. Soc. 129, 139-154 (2007).
91. L. Angew. Chem. Int. Ed. 48, 4318-4322 (2009).
92. Horne, W. S., Boersma, M. D., Windsor, M. A. & Gellman, S. H. Sequence-based design of α/β-peptide foldamers that mimic BH3 domains. Ang e w. Chem. Int. Ed. 47, 2853-2856 (2008).
93. L recognition by a BH3-mimetic α/β-peptide generated by sequence-based design. ChemBioChem 12, 2025-2032 (2011).
94. Boersma, M. D. et al. Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: Analogues of the Bim BH3 domain. J. Am. Chem. Soc. 134, 315-323 (2011).
95. Horne, W. S. et al. Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers. Proc. Natl Acad. Sci. USA 106, 14751-14756 (2009).
96. Johnson, L. M. et al. Enhancement of α-helix mimicry by an α/β-peptide foldamer via incorporation of a dense ionic side-chain array. J. Am. Chem. Soc. 134, 7317-7320 (2012).
97. Hara, T., Durell, S. R., Myers, M. C. & Appella, D. H. Probing the structural requirements of peptoids that inhibit hDM2-p53 interactions. J. Am. Chem. Soc. 128, 1995-2004 (2006).
98. Hayashi, R. et al. N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53. Bioorg. Med. Chem. 17, 7884-7893 (2009).
99. Sawada, T. & Gellman, S. H. Structural mimicry of the α-helix in aqueous solution with an isoatomic α/β/γ-peptide backbone. J. Am. Chem. Soc. 133, 7336-7339 (2011).
100. Patgiri, A., Joy, S. T. & Arora, P. S. Nucleation efects in peptide foldamers. J. Am. Chem. Soc. 134, 11495-11502 (2012).
101. Fasan, R. et al. Structure-activity studies in a family of β-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. ChemBioChem 7, 515-526 (2006).
102. Ripka, A. S. & Rich, D. H. Peptidomimetic design. Curr. Opin. Chem. Biol. 2, 441-452 (1998).
103. Nolan, W. P., Ratclife, G. S. & Rees, D. C. The synthesis of 1, 6-disubstituted indanes which mimic the orientation of amino acid side-chains in a protein alpha-helix motif. Tetrahedron Lett. 33, 6879-6882 (1992).
104. Horwell, D. C., Howson, W., Ratclife, G. S. & Willems, H. M. G. The design of dipeptide helical mimetics: The synthesis tachykinin receptor afnity and conformational analysis of 1, 1, 6-trisubstituted indanes. Bioorg. Med. Chem. 4, 33-42 (1996).
105. Orner, B. P., Ernst, J. T. & Hamilton, A. D. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J. Am. Chem. Soc. 123, 5382-5383 (2001).
106. Ernst, J. T. et al. Design of a protein surface antagonist based on α-helix mimicry: Inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. 41, 278-282 (2002).
107. L antagonist based on α-helix mimicry. J. Am. Chem. Soc. 124, 11838-11839 (2002).
108. L. J. Am. Chem. Soc. 127, 10191-10196 (2005).
109. L, Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax-and Bim-dependent manner. J. Biol. Chem. 286, 9382-9392 (2011).
110. L/Bak interaction. J. Am. Chem. Soc. 127, 5463-5468 (2005).
111. Rodriguez, J. M., Nevola, L., Ross, N. T., Lee, G.-i. & Hamilton, A. D. Synthetic inhibitors of extended helix-protein interactions based on a biphenyl 4, 4′-dicarboxamide scafold. ChemBioChem 10, 829-833 (2009).
112. Rodriguez, J. M. & Hamilton, A. D. Benzoylurea oligomers: synthetic foldamers that mimic extended α-helices. Angew. Chem. Int. Ed. 46, 8614-8617 (2007).
113. L/Bak binding interface. ChemMedChem 4, 649-656 (2009).
114. Biros, S. M. et al. Heterocyclic α-helix mimetics for targeting protein-protein interactions. Bioorg. Med. Chem. Lett. 17, 4641-4645 (2007).
115. Cummings, C. G., Ross, N. T., Katt, W. P. & Hamilton, A. D. Synthesis and biological evaluation of a 5-6-5 imidazole-phenyl-thiazole based α-helix mimetic. Org. Lett. 11, 25-28 (2009).
116. Huc, I. Aromatic oligoamide foldamers. Eur. J. Org. Chem. 2004, 17-29 (2004).
117. Ernst, J. T., Becerril, J., Park, H. S., Yin, H. & Hamilton, A. D. Design and application of an α-helix-mimetic scafold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew. Chem. Int. Ed. 42, 535-539 (2003).
118. Saraogi, I. et al. Synthetic α-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation. Angew. Chem. Int. Ed. 49, 736-739 (2010).
119. Yin, H., Frederick, K. K., Liu, D., Wand, A. J. & DeGrado, W. F. Arylamide derivatives as peptidomimetic inhibitors of calmodulin. Org. Lett. 8, 223-225 (2005).
120. Ahn, J. M. & Han, S. Y. Facile Synthesis of benzamides to mimic an α-helix. Tetrahedron Lett. 48, 3543-3547 (2007).
121. Plante, J. et al. Synthesis of functionalised aromatic oligamide rods. Org. Biomol. Chem. 6, 138-146 (2008).
122. Saraogi, I., Incarvito, C. D. & Hamilton, A. D. Controlling curvature in a family of oligoamide α-helix mimetics. Angew. Chem. Int. Ed. 47, 9691-9694 (2008).
123. L inhibitors. Org. Biomol. Chem. 10, 2928-2933 (2012).
124. Plante, J. P. et al. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. Chem. Commun. 5091-5093 (2009).
125. Shaginian, A. et al. Design, synthesis, and evaluation of an α-helix mimetic library targeting protein-protein interactions. J. Am. Chem. Soc. 131, 5564-5572 (2009).
126. Whitby, L. R. et al. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library. Bioorg. Med. Chem. Lett. 22, 2861-2865 (2012).
127. Azzarito, V. et al. 2-O-Alkylated para-benzamide α-helix mimetics: The role of scafold curvature. Org. Biomol. Chem. 10, 6469-6472 (2012).
128. Lu, F. et al. Proteomimetic libraries: Design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J. Comb. Chem. 8, 315-325 (2006).
129. Shahian, T. et al. Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nature Chem. Biol. 5, 640-646 (2009).
130. Campbell, F., Plante, J. P., Edwards, T. A., Warriner, S. L. & Wilson, A. J. N-Alkylated oligoamide α-helical proteomimetics. Org. Biomol. Chem. 8, 2344 (2010).
131. Long, K., Edwards, T. A. & Wilson, A. J. Microwave assisted solid phase synthesis of highly functionalized N-alkylated oligobenzamide α-helix mimetics. Biorg. Med. Chem. http://dx.doi.org/10.1016/j.bmc.2012. 09.053 (2012).
132. Lee, J. H. et al. Novel pyrrolopyrimidine-based α-helix mimetics: Cell-permeable inhibitors of protein-protein interactions. J. Am. Chem. Soc. 133, 676-679 (2011).
133. Kim, I. C. & Hamilton, A. D. Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an α-helix. Org. Lett. 8, 1751-1754 (2006).
134. Marimganti, S., Cheemala, M. N. & Ahn, J. M. Novel amphiphilic alpha-helix mimetics based on a bis-benzamide scafold. Org. Lett. 11, 4418-4421 (2009).
135. Tošovská, P. & Arora, P. S. Oligooxopiperazines as nonpeptidic α-helix mimetics. Org. Lett. 12, 1588-1591 (2010).
136. Becerril, J. & Hamilton, A. D. Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew. Chem. Int. Ed. 46, 4471-4473 (2007).
137. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23, 3-25 (1997).
138. Lichtiger, S. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl. J. Med. 330, 1841-1845 (1994).